Tygh Capital Management’s Emergent Biosolutions EBS Stock Holding History

Tygh Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-56,334	Closed	-$5.05M	–	91
2020 Q4	$5.05M	Sell	56,334 -74,192	-57%	-$6.81M	0.79%	58
2020 Q3	$13.5M	Sell	130,526 -12,870	-9%	-$1.39M	2.56%	2
2020 Q2	$11.3M	Buy	143,396 +664	+0.5%	+$49.5K	2.36%	6
2020 Q1	$8.26M	Buy	142,732 +25,570	+22%	+$1.47M	1.85%	19
2019 Q4	$6.32M	Sell	117,162 -181,326	-61%	-$9.83M	1.04%	45
2019 Q3	$15.6M	Buy	298,488 +202,527	+211%	+$9.44M	2.77%	4
2019 Q2	$4.64M	Buy	+95,961	New	+$4.6M	0.79%	60

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tygh Capital Management's EBS Position: Q1 2021 in Review

Tygh Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 56,334 shares — an estimated $5.05M sold.

Tygh Capital Management first reported a position in EBS in Q2 2019 and held it in 7 quarters. The position peaked at $15.6M in Q3 2019. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

Tygh Capital Management reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
Tygh Capital Management sold 56,334 Emergent Biosolutions shares in Q1 2021, an estimated $5.05M.
Tygh Capital Management first reported a position in Emergent Biosolutions in Q2 2019 and held it in 7 quarters.
Tygh Capital Management's Emergent Biosolutions position peaked at $15.6M in Q3 2019.
340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Tygh Capital Management's 13F filing for Q1 2021, filed 10 May 2021.